ATE428780T1 - Verfahren zur zubereitung von antisense oligonukleotiden - Google Patents

Verfahren zur zubereitung von antisense oligonukleotiden

Info

Publication number
ATE428780T1
ATE428780T1 AT98908022T AT98908022T ATE428780T1 AT E428780 T1 ATE428780 T1 AT E428780T1 AT 98908022 T AT98908022 T AT 98908022T AT 98908022 T AT98908022 T AT 98908022T AT E428780 T1 ATE428780 T1 AT E428780T1
Authority
AT
Austria
Prior art keywords
antisense oligonucleotides
preparing antisense
preparing
sequence
antisense oligonucleotide
Prior art date
Application number
AT98908022T
Other languages
English (en)
Inventor
Karl-Hermann Schlingensiepen
Wolfgang Brysch
Original Assignee
Biognostik Ges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Ges filed Critical Biognostik Ges
Application granted granted Critical
Publication of ATE428780T1 publication Critical patent/ATE428780T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
AT98908022T 1997-01-31 1998-01-30 Verfahren zur zubereitung von antisense oligonukleotiden ATE428780T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97101531A EP0856579A1 (de) 1997-01-31 1997-01-31 Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
PCT/EP1998/000497 WO1998033904A2 (en) 1997-01-31 1998-01-30 An antisense oligonucleotide preparation method

Publications (1)

Publication Number Publication Date
ATE428780T1 true ATE428780T1 (de) 2009-05-15

Family

ID=8226428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908022T ATE428780T1 (de) 1997-01-31 1998-01-30 Verfahren zur zubereitung von antisense oligonukleotiden

Country Status (8)

Country Link
US (2) US6972171B1 (de)
EP (4) EP0856579A1 (de)
JP (1) JP2001511000A (de)
AT (1) ATE428780T1 (de)
AU (1) AU6617898A (de)
DE (1) DE69840748D1 (de)
ES (1) ES2323252T3 (de)
WO (1) WO1998033904A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
EP1055366A1 (de) * 1999-05-26 2000-11-29 Boehringer Ingelheim International GmbH Verwendung von transgenen mäusen mit fehlender expression von jun-b in myeloidzellen
EP1296643A4 (de) * 1999-09-17 2005-07-27 Isis Pharmaceuticals Inc Antisense-modulation der beta-tgf expression
GB9929487D0 (en) 1999-12-15 2000-02-09 Zeneca Ltd Antisense oligonucleotides
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
AU2013200739B2 (en) * 1999-12-29 2015-08-27 Basf Enzymes Llc Nitrilases
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US6613567B1 (en) * 2000-09-15 2003-09-02 Isis Pharmaceuticals, Inc. Antisense inhibition of Her-2 expression
DE10048091A1 (de) * 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
KR100946980B1 (ko) * 2000-12-01 2010-03-17 리스판스 지네틱스, 인크. 표피 성장 인자 수용체 및 ｈｅｒ2-ｎｅｕ 유전자 발현 및 이들 수준과 생존율의 상관성을 측정하는 방법
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7807801B2 (en) * 2003-08-05 2010-10-05 Avi Biopharma Inc. Oligonucleotide analog and method for treating flavivirus infections
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
PT1877070E (pt) 2005-05-05 2009-03-13 Antisense Pharma Gmbh Utilização terapêutica de oligonucleótidos anti-sentido tgf-beta2
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
US8093369B2 (en) * 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
CA2667971C (en) 2006-11-01 2017-04-18 Gary Weisinger Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
WO2008106662A2 (en) 2007-03-01 2008-09-04 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
EP2238249A2 (de) * 2007-12-07 2010-10-13 Santaris Pharma A/S Rna-antagonistverbindungen zur modulation von mcl-1
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010277554B2 (en) * 2009-07-30 2015-02-19 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
EP2524038A4 (de) * 2010-01-12 2013-11-20 Isis Pharmaceuticals Inc Modulation der transformierung einer wachstumsfaktor-beta-1-expression
JP5863670B2 (ja) 2010-01-19 2016-02-17 ノースウェスタン ユニバーシティ 核酸および／または他の構成要素を含有している合成ナノ構造体
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
EP3164113B1 (de) 2014-06-04 2019-03-27 Exicure, Inc. Multivalente freisetzung von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
EA201790802A1 (ru) 2014-10-06 2017-08-31 Экзикьюр, Инк. Соединения против tnf
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871861A (en) * 1987-07-06 1989-10-03 Olin Corporation Substituted 5-amidotetrazoles
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
EP0724447B1 (de) * 1991-10-24 2003-05-07 Isis Pharmaceuticals, Inc. Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US6455689B1 (en) * 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
AU6984594A (en) 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
WO1995002422A1 (en) * 1993-07-12 1995-01-26 Weltman Joel K Method for conjugating nucleotides and nucleosides to disulfide-, maleimide-, and thiol-containing compounds
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
WO1996031600A1 (en) * 1995-04-03 1996-10-10 Hybridon, Inc. Method of modulating gene expression without depleting complement

Also Published As

Publication number Publication date
US6972171B1 (en) 2005-12-06
EP2028274A3 (de) 2012-06-13
EP0856579A1 (de) 1998-08-05
EP2028274A2 (de) 2009-02-25
EP1889911A3 (de) 2008-06-11
JP2001511000A (ja) 2001-08-07
DE69840748D1 (de) 2009-05-28
WO1998033904A3 (en) 1999-05-14
US7563778B2 (en) 2009-07-21
EP1012267B1 (de) 2009-04-15
WO1998033904A2 (en) 1998-08-06
EP1889911A2 (de) 2008-02-20
US20050130927A1 (en) 2005-06-16
AU6617898A (en) 1998-08-25
EP1012267A2 (de) 2000-06-28
ES2323252T3 (es) 2009-07-09

Similar Documents

Publication Publication Date Title
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
DE69837681D1 (de) Verfahren zur herstellung von 1,3-diolen
DE69801489D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
DE69734263D1 (de) Verfahren zur Isolierung von Ribonucleinsäuren.
ATE277937T1 (de) Verfahren zur herstellung von 9-(2- (diethylphosphonomethoxy)ethyl)-adenin
DE69932609D1 (de) Verfahren zur herstellung von 1-chloro-1,1,3,3,3-pentafluorpropan
DE69813538D1 (de) Verfahren zur herstellung von halbsynthetischen statinen vianeue zwischenprodukte
DE59813077D1 (de) Verfahren zur Herstellung strahlungshärtbarer, Urethangruppen enthaltender Prepolymere
DE69729476D1 (de) Tiefdruckverfahren zur herstellung von strukturierten schleifoberflächen
DE59813182D1 (de) Verfahren zur herstellung von aryloligoaminen
ATE236187T1 (de) Verfahren zur herstellung von 2'-fluoro-5-methyl- beta-l-arabino-furanosyluridin
DE59803946D1 (de) Verfahren zur herstellung von polyamiden
DE69731112D1 (de) Verfahren zur synthese von phosphorothioat-oligonukelotiden
DE69805061D1 (de) Verfahren zur herstellung von alkylpolyglykosiden
ATA4197A (de) Enantioselektives verfahren zur herstellung von (s)-cyanhydrinen
DE59802898D1 (de) Verfahren zur herstellung von aromatischen nitrilen
DE59805920D1 (de) Verfahren zur herstellung von oxazaphosphorin-2-aminen
DE69819191D1 (de) Verfahren zur herstellung von pentafluorethan
DE69920003D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE69812702D1 (de) Verfahren zur herstellung von keramikformen
DE69724659D1 (de) Verfahren zur hydroxylierung von 1,4-dichlorbenzol
DE69811871D1 (de) Verfahren zur herstellung von uridine diphosphat-n-acetylglucosamine (13.04.99)
EP1118659A4 (de) Expressionssysteme zur funktionellen expression von nukleinsäuren
ATE208368T1 (de) Verfahren zur herstellung von 3,4 disubstituirten dinitroanilinen
DE69811100D1 (de) Verfahren zur herstellung von 1,2-propandiol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012267

Country of ref document: EP